NCT07740603Not yet recruiting
Study of CD38 and CD56 in Chronic Myeloid Leukemia
Aberrant Expression of CD56 on CD38 Positive Neutrophils as a Novel Diagnostic Tool in Chronic Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow. The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 25 Jul 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Sohag University
- NCT number
- NCT07740603
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Sept 2026 to the primary completion date, 1 Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- other hematological diseases
Who the study is looking for
- patients with chronic myeloid leukemia
Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.